CDC's Advisory Committee on Immunization Practices (ACIP) — agendas, slides, recommendations, and meeting materials covering vaccine policy decisions.
Get an AI answer drawn only from the CDC ACIP — Vaccine Advisory Committee documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Centers for Disease Control and Prevention Evidence to Recommendations Framework Respiratory Syncytial Virus (RSV) in Adults GSK adjuvanted RSVpreF3 vaccine in older adults Pfizer bivalent RSVpreF vaccine in older adults Michael Melgar, MD Lead, Adult RSV ACIP Work Group ACIP Meeting February 23, 2023 Evidence to Recommendations (EtR ) Framework Poli cy Questions Should vaccination with GSK RSVpreF3 vaccine (120µg antigen + AS01E adjuvant, 1 dose IM),…
• • • • For more information, contact CDC 1-800-CDC- INFO (232- 4636) TTY: 1 -888- 232-6348 www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
CHIKUNGUNYA VACCINES Beth Bell, MD, MPH Chair, ACIP Chikungunya Vaccines Work GroupACIP Meeting February 23, 2023 Background Valneva completed submission of Biologics License Application (BLA) for their chikungunya vaccine to FDA in December 2022 No chikungunya vaccine ever licensed in United States or globally No existing ACIP chikungunya vaccine recommendations Chikungunya Vaccines Work Group formed in May 2022 to develop policy options for ACIP’s consideration for use of chikungunya…
National Center for Emerging and Zoonotic Infectious Diseases GLOBAL EPIDEMIOLOGY OF CHIKUNGUNYA Susan Hills, MBBS, MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP meeting, February 23, 2023 Chikungunya Mosquito -b orne viral disease –Primarily human -mo squito -human transmission –Mainly A edes aegypti and Aedes albopictus Clinically characterized by acute onset of fever and oft en severe…
National Center for Emerging and Zoonotic Infectious Diseases Chikungunya in US travelers Nicole Lindsey, MS CDC Deputy Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Centers for Disease Control and Prevention National surveillance data for chikungunya virus disease in US travelers Data presented include confirmed and probable cases in residents of US states reported to CDC (excludes US territories and associated states) Prior to 2006, very rarely identified in US…
National Center for Emerging and Zoonotic Infectious Diseases Chronic arthralgia after chikungunya Nicole Lindsey, MS CDC Deputy Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Centers for Disease Control and Prevention Clinical outcomes of chikungunya virus disease Acute symptoms typically resolve in 7 -10 days Mortality is very rare Significant proportion of patients have continued or recurrent arthralgia in months and years following acute illness Additional long- term…
National Center for Emerging and Zoonotic Infectious Diseases WORK GROUP PLANS AND TIMELINES Nicole Lindsey, MS CDC Deputy Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Centers for Disease Control and Prevention ACIP meeting February 23, 2023 Work Group timeline (tentative) Dec Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr2024 (Today) Global epidemiology, US traveler, and chronic arthralgia dataPresent EtR to ACIPPresent to ACIP other data…
AA ACC CII IPP PDD Dee enn ngg guu uee eVV Vaa acc ccc cii inn nee e WW Woo orr rkk kgg grr roo ouu upp pACIP Dengue Vaccine Workgroup Wilbur Chen, MD, MSc ACIP Member and Workgroup Chair Advisory Committee on Immunization Practices ACIP Meeting February 23, 2023 Dengue Virus DENV-1, 2, 3, 4 • Lifelong DENV type-specific immunity • Short-term cross-immunity (~1–2 years) • A second dengue infection is the most important risk factor for severe…
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. COVID -19 Vaccine Policy and Next Steps October 26, 2023 Megan Wallace, DrPH, MPH COVID -19 Epidemiology 3Trends in weighted variant proportion estimates and Nowcast –…
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Pneumococcal Vaccines Work Group October 2023, ACIP meeting October 26, 2023 Miwako Kobayashi, MD, MPH •The Pneumococcal Vaccines Work Group: •Reviews current data on…
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Effectiveness of Maternal Influenza Vaccination during Pregnancy against Influenza- associated Hospitalizations & ED Visits in Infants <6 Months of Age Samantha M.…
1 WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Influenza Division, National Center for Immunization and Respiratory Diseases Update on Influenza B/Yamagata Surveillance Rebecca Kondor, PhD Interim Director, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza Lead, Genomics Analysis Team Virology, Surveillance and Diagnosis Branch –Influenza Division –NCIRD 2 WHO Collaborating Center for Surveillance, Epidemiology and Control…
1 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group Sarah S. Long, MD Chair, Maternal/Pediatric RSV Work Group ACIP General Meeting September 22, 2023…
RSVpreF Vaccine Safety Surveillance in Pregnancy from The Vaccine Safety Datalink Malini DeSilva, MD, MPH ACIP meeting September 22, 20231 Vaccine Safety Datalink (VSD), 2023 •Collaborative project between CDC and integrated healthcare organizations •Monitors safety of vaccines used in the U.S., primarily through real -world data of rare and serious events following vaccination •Includes data on ~15.5 million individuals across all sites annually •~ 115,000 annual live births •Data…
Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases Maternal RSV vaccine safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) and V -safe Pedro L. Moro, MD, MPH Immunization Safety Office Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices September 22, 2023 2Co-managed by CDC and FDA Vaccine Adverse Event Reporting System (VAERS) Vaccine Adverse Event Reporting System +…
Economic Analysis of RSVpreF Maternal Vaccination David W. Hutton, PhD, MS Professor, Health Management and Policy, School of Public Health Professor of Global Public Health, School of Public Health Professor, Industrial and Operations Engineering, College of Engineering University of MichiganSeptember 22, 2023 Research team University of Michigan •David Hutton, PhD •Lisa Prosser, PhD •Angela Rose, MPH •Kerra Mercon , MSCDC •Jefferson Jones, MD, MPH, FAAP •Mila Prill, MSPH •Meredith McMorrow,…
Economics of Preventing Respiratory Syncytial Virus Disease among US Infants by Maternal Vaccination Prior to Birth A SUMMARY REPORT COMPARING MODELS FROM: Pfizer AND University of Michigan and CDC Ismael R. Ortega -Sanchez, PhD NCIRD/CDC ACIP Meeting, September 22, 2023 1Disclaimer : The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. National Center for Immunization &…
1 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Evidence to Recommendations Framework Updates Pfizer Maternal RSVpreF Vaccine ACIP General Meeting September 22, 2023Katherine E. Fleming -Dutra, MD Co-lead,…
1 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Proposed clinical considerations for maternal RSVPreF vaccine and nirsevimab Jefferson Jones MD MPH FAAP CDR USPHS Co-Lead, Respiratory Syncytial Virus Vaccines…
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Maternal RSV Vaccine Implementation Considerations Georgina Peacock, MD, MPH Immunization Services Division Centers for Disease Control and Prevention ▪Vaccine storage,…